X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs GLENMARK PHARMA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA GLENMARK PHARMA TORRENT PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 36.6 17.6 207.8% View Chart
P/BV x 6.5 3.1 209.7% View Chart
Dividend Yield % 0.8 0.3 232.6%  

Financials

 TORRENT PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
GLENMARK PHARMA
Mar-18
TORRENT PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,550930 166.7%   
Low Rs1,144517 221.0%   
Sales per share (Unadj.) Rs354.7322.6 109.9%  
Earnings per share (Unadj.) Rs40.128.5 140.7%  
Cash flow per share (Unadj.) Rs64.239.2 163.9%  
Dividends per share (Unadj.) Rs14.002.00 700.0%  
Dividend yield (eoy) %1.00.3 376.2%  
Book value per share (Unadj.) Rs273.1183.0 149.3%  
Shares outstanding (eoy) m169.22282.17 60.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.82.2 169.3%   
Avg P/E ratio x33.625.4 132.3%  
P/CF ratio (eoy) x21.018.5 113.6%  
Price / Book Value ratio x4.94.0 124.7%  
Dividend payout %34.97.0 497.6%   
Avg Mkt Cap Rs m227,897204,206 111.6%   
No. of employees `00014.713.7 107.2%   
Total wages/salary Rs m11,35318,718 60.6%   
Avg. sales/employee Rs Th4,083.06,636.8 61.5%   
Avg. wages/employee Rs Th772.31,364.7 56.6%   
Avg. net profit/employee Rs Th461.3586.1 78.7%   
INCOME DATA
Net Sales Rs m60,02191,031 65.9%  
Other income Rs m2,988914 327.0%   
Total revenues Rs m63,00991,945 68.5%   
Gross profit Rs m13,49316,154 83.5%  
Depreciation Rs m4,0863,019 135.4%   
Interest Rs m3,0852,856 108.0%   
Profit before tax Rs m9,31011,193 83.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5293,155 80.2%   
Profit after tax Rs m6,7818,039 84.4%  
Gross profit margin %22.517.7 126.7%  
Effective tax rate %27.228.2 96.4%   
Net profit margin %11.38.8 127.9%  
BALANCE SHEET DATA
Current assets Rs m52,62369,887 75.3%   
Current liabilities Rs m52,02232,879 158.2%   
Net working cap to sales %1.040.7 2.5%  
Current ratio x1.02.1 47.6%  
Inventory Days Days12081 146.9%  
Debtors Days Days7693 81.5%  
Net fixed assets Rs m85,01628,892 294.3%   
Share capital Rs m846282 299.9%   
"Free" reserves Rs m45,37651,353 88.4%   
Net worth Rs m46,22251,635 89.5%   
Long term debt Rs m41,11541,418 99.3%   
Total assets Rs m142,432125,954 113.1%  
Interest coverage x4.04.9 81.7%   
Debt to equity ratio x0.90.8 110.9%  
Sales to assets ratio x0.40.7 58.3%   
Return on assets %6.98.6 80.1%  
Return on equity %14.715.6 94.2%  
Return on capital %14.215.1 94.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58036,317 40.1%   
Fx outflow Rs m3,6009,720 37.0%   
Net fx Rs m10,98026,598 41.3%   
CASH FLOW
From Operations Rs m8,94216,481 54.3%  
From Investments Rs m-47,070-10,133 464.5%  
From Financial Activity Rs m34,174-4,685 -729.4%  
Net Cashflow Rs m-3,6551,770 -206.5%  

Share Holding

Indian Promoters % 71.5 48.3 148.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 6.9 101.7%  
FIIs % 12.6 34.4 36.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.5 83.8%  
Shareholders   26,511 56,727 46.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   ELDER PHARMA  TTK HEALTHCARE  SHASUN PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 404 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets continued their momentum during closing hours and ended the day on a strong note. Gains were largely seen in the metal sector and oil & gas sector.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 20, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - DR. DATSONS LABS COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS